Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14751009 | 0.92 | CNR2 (0.34) | CNR2DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2378332 | 0.90 | JAK3 (0.41) | CNR2DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2379093 | 0.88 | JAK2 (0.45) | CNR2DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2379097 | 0.88 | JAK2 (0.45) | CNR2DGAT1JAK2JAK1JAK3 | |
| SCHEMBL1371873 | 0.85 | DGAT1 (0.39) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL1370337 | 0.85 | DGAT1 (0.38) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL2380156 | 0.84 | JAK2 (0.40) | CNR2DGAT1JAK2JAK1JAK3 | |
| SCHEMBL12145968 | 0.82 | DGAT1 (0.38) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL1372324 | 0.82 | DGAT1 (0.38) | DGAT1JAK2JAK1JAK3 | |
| SCHEMBL14751092 | 0.81 | DGAT1 (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | CNR2 3149/4885DGAT1 4811/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.